Clinical trials offer hope for people living with kidney disease, but success depends on whether patients feel heard, trusted, and genuinely included in the research process. A growing movement in nephrology is shifting how researchers approach kidney disease studies, moving away from top-down recruitment toward authentic partnerships with patients and their communities. This change is reshaping what clinical trials look like and who participates in them. What's Driving More Kidney Patients Into Clinical Trials? For decades, clinical trials have been seen as a last resort for people with kidney disease, or something that happens to them rather than with them. But that dynamic is changing. Researchers and patient advocates are now recognizing that the power of being asked matters. When patients feel genuinely invited to participate, when their concerns are addressed, and when they see themselves reflected in the research team, enrollment increases. The shift reflects a broader understanding that clinical trials aren't just about collecting data. They're about building trust in communities that have historically been left out of medical research. For kidney disease patients, many of whom manage complex treatment regimens and navigate healthcare systems that don't always serve them well, the decision to participate in a trial is deeply personal. How Are Researchers Building Better Partnerships With Kidney Patients? - Community Engagement Teams: Leading institutions are hiring dedicated staff to work directly with kidney disease communities, listening to their concerns and helping design studies that address real patient needs rather than just researcher priorities. - Equity-Focused Leadership: Researchers like Dr. Nadine Barrett, a Professor in the Department of Social Sciences and Health Policy at Wake Forest School of Medicine and inaugural Senior Associate Dean of Community Engagement and Equity in Research, are bringing health disparities expertise into clinical trial design. Dr. Barrett develops multi-level interventions to address implicit bias, structural and systemic racism, and inequities that limit access to quality research and trustworthy healthcare among underserved and marginalized populations. - Patient Voices in Research Planning: Kidney disease patients and advocates are now sitting on research advisory boards and steering committees, helping shape which questions get studied and how trials are conducted. - Transparency About Trial Participation: Researchers are being more upfront about what clinical trial participation actually involves, addressing safety concerns head-on and explaining why patient input matters to the broader kidney disease community. These changes reflect a recognition that clinical trials work better when they're designed with patients, not just for them. When kidney disease patients see themselves represented in research teams and feel their lived experience is valued, they're more likely to enroll and stay engaged throughout the study. Who Are the Kidney Patients Leading This Change? Patient advocates with lived experience of kidney disease are becoming central figures in clinical research. Glenda Roberts, Director of Communications and Patient Engagement at the Mount Sinai Center for Kidney Disease Innovation, managed her kidney disease progression for over 40 years using diet and exercise before going on dialysis. Since receiving a kidney transplant in 2010, she has completed nine half marathons and now brings the patient voice to several National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) government and industry research efforts, including the Kidney Precision Medicine Project and the American Society of Nephrology's Current and Emerging Threats Steering Committee. Similarly, Luz Baqueiro, a patient advocate with the National Kidney Foundation (NKF), was diagnosed with end-stage renal disease (ESRD) in 2019. After relying on emergency in-hospital dialysis for a year due to limited resources in Georgia, she received a kidney transplant in August 2021 through self-determination and community support. Now she provides feedback and helps develop new initiatives to better support the Latin American community affected by chronic kidney disease while raising awareness of barriers faced by patients living with renal failure. These patient leaders bring something researchers can't replicate: authentic understanding of what it means to live with kidney disease. Their participation in clinical trial design ensures that studies address questions that actually matter to patients, not just to the medical establishment. Why Does Patient Trust Matter So Much in Kidney Research? Kidney disease disproportionately affects certain communities, and historical inequities in healthcare have created justified skepticism about medical research. When researchers approach kidney disease patients with genuine respect for their expertise and concerns, it changes everything. Patients are more likely to enroll, more likely to complete the study, and more likely to recommend participation to others in their community. The National Kidney Foundation's podcast series "Hot Topics in Kidney Health" now regularly features conversations between researchers, clinicians, and patient advocates about clinical trials, xenotransplantation breakthroughs, and other emerging treatments. These discussions are updated monthly and focus on the latest in kidney research, care, and treatment, making complex science accessible to patients considering whether to participate in studies. For kidney disease patients weighing whether to join a clinical trial, the message from researchers and advocates is clear: your voice matters, your questions deserve answers, and your participation could help shape the future of kidney care for everyone. The clinical trials of tomorrow are being built by listening to patients today.
